Cellular Morphogenesis in the *Saccharomyces cerevisiae* Cell Cycle: Localization of the CDC11 Gene Product and the Timing of Events at the Budding Site

**SUSAN K. FORD AND JOHN R. PRINGLE**

Department of Biology, The University of Michigan, Ann Arbor

**ABSTRACT**  
The *Saccharomyces cerevisiae* CDC3, CDC10, CDC11, and CDC12 genes encode a family of homologous proteins that are not closely related to other known proteins [Haarer BK, Ketcham SR, Ford SK, Ashcroft DJ, and Pringle JR (submitted)]. Temperature-sensitive mutants defective in any of these four genes display essentially identical pleiotropic phenotypes that include abnormal cell-wall deposition and bud growth, an inability to complete cytokinesis, and a failure to form the ring of 10 nm filaments that normally lies directly subjacent to the plasma membrane in the neck region of budding cells. We showed previously that the CDC3 and CDC12 gene products localize to the region of the mother-bud neck and are probably constituents of the ring of 10 nm filaments. We now report the generation of polyclonal antibodies specific for the CDC11 product (Cdc11p) and the use of these antibodies in immunofluorescence experiments with wild-type and mutant cells. The results suggest that Cdc11p is also a constituent of the filament ring, and thus support the hypothesis that the *S. cerevisiae* 10 nm filaments represent a novel type of eukaryotic cytoskeletal element. Cdc11p and actin both localize to the budding site well in advance of bud emergence and at approximately the same time, and both proteins also remain localized at the old budding site for some time after cytokinesis. Cdc11p also localizes to regions of cell-wall reorganization in mating cells and in cells responding to purified mating pheromone. Surprisingly, most preparations of affinity purified Cdc11p-specific antibodies also stained the nuclear and cytoplasmic microtubules. Although this staining probably reflects the existence of an epitope shared by Cdc11p and some microtubule-associated protein, the possibility that a fraction of the Cdc11p is associated with the microtubules could not be eliminated.

**Key words:** Actin function, cell wall, cytoskeleton, fusion proteins, mating, 10 nm filaments, yeast

**INTRODUCTION**

A fundamental problem in cell and developmental biology is to understand the molecular mechanisms that control the generation of cell shape and intracellular three-dimensional organization. The mitotic cell-division cycle of the yeast *Saccharomyces cerevisiae* includes a variety of morphogenetic events that involve both localized cell-surface changes and the specific positioning of intracellular organelles [Pringle and Hartwell, 1981; Cabib et al., 1982; Pringle et al., 1986]. As in other eukaryotes, cytoskeletal elements, including both microtubules [Byers, 1981; Kilmartin and Adams, 1984; Adams and Pringle, 1984; Huffaker et al., 1988; Jacobs et al., 1988] and the actin system [Kilmartin and Adams, 1984; Adams and Pringle, 1984; Novick and Botstein, 1985; Drubin et al., 1988; Adams et al., 1989; Haarer et al., 1990], are believed to play important roles at these processes.

Yeast cells contain at least one other cytoskeletal element, a highly ordered array of filaments ~10 nm in diameter that lies directly inside the cytoplasmic membrane in the region of the mother-bud neck [Byers and Goetsch, 1976a; Byers, 1981]. Electron microscopy has suggested that these filaments appear just prior to or coincident with bud emergence and are lost just prior to cytokinesis. Temperature-sensitive mutants defective in any of four different cell-division cycle genes (CDC3, CDC10, CDC11, and CDC12) fail to form these filaments at restrictive temperature [Byers and Goetsch, 1976b; Adams, 1984] and display pleiotropic morphogenetic abnormalities including abnormal organization of the cell wall at the base of the bud (no normal chitin ring is formed), hyperpolarized bud.
growth, and a failure to complete cytokinesis [Hartwell, 1971; Adams, 1984; Adams and Pringle, 1984; Slater et al., 1985]. As the mutant cells continue to replicate DNA, undergo nuclear division, and form new buds, the mutants arrest as multinucleate cells with multiple, abnormally elongated buds.

Previous studies have shown that CDC3, CDC10, CDC11, and CDC12 encode a family of proteins that are 25–37% identical in amino acid sequence [Haarer et al., submitted]. In addition, antibodies specific for the CDC3, CDC10, and CDC12 products (Cdc3p, Cdc10p, and Cdc12p) have been used to show by immunofluorescence that these proteins localize to the region occupied by the ring of 10 nm filaments and are probably constituents of this cytoskeletal element [Haarer and Pringle, 1987; Kim et al., 1991; Kim et al., manuscript in preparation]. Here we report the preparation of antibodies specific for the CDC11 gene product (Cdc11p) and the use of these antibodies to localize this protein within cells in patterns very similar to those observed for Cdc3p, Cdc10p, and Cdc12p. We have also examined the timing of arrival of both Cdc11p and actin at presumptive budding sites, the timing of departure of these proteins from old budding sites after cytokinesis, and the localization of Cdc11p in cells undergoing morphogenetic changes during mating or in response to mating pheromone [Lipke et al., 1976; Schekman and Brawley, 1979; Tkacz and MacKay, 1979; Hašek et al., 1987; Trueheart et al., 1987].

**MATERIALS AND METHODS**

**Reagents**

T4 DNA ligase, restriction endonucleases, and large (Klenow) fragment of DNA polymerase were obtained from Bethesda Research Laboratories (Gaithersburg, MD) or New England BioLabs (Beverly, MA). Calf intestine alkaline phosphatase was obtained from Boehringer Mannheim (Indianapolis, IN). Freund's complete and incomplete adjuvants, 33-iodoacrylic acid, isopropyl β-D-thio-galactopyranoside (IPTG), DAPI, Coomassie Brilliant Blue R, Ponceau S, α-factor, and nocodazole were obtained from Sigma (St. Louis, MO). FITC-conjugated and rhodamine-conjugated goat anti-rabbit-IgG (IgG fraction) and rhodamine-conjugated goat anti-rat-IgG (IgG fraction) were obtained from United States Biochemical (Cleveland, OH). Rat anti-tubulin monoclonal antibody YOL1/34 was a gift from J. Kilmartin [Kilmartin et al., 1982]. Rhodamine-phalloidin was obtained from Molecular Probes (Eugene, OR) as a 3.3 μM stock in methanol. “EIA grade” affinity-purified goat anti-rabbit-IgG (H + L) conjugated to horseradish peroxidase (HRP) was obtained from Bio-Rad (Richmond, CA). Nitrocellulose paper BA 85 was obtained from Schleicher & Schuell (Keene, NH).

**Plasmids, Strains, and Growth Conditions**

Plasmid pUR288 and E. coli strain BMH71-18 were handled essentially as described previously [Messing et al., 1977; Rüther and Müller-Hill, 1983]. Plasmid pATH3 was provided by T.J. Koerner and A. Tzagoloff and was propagated in E. coli strain HB101 [Maniatis et al., 1982] as described previously [Haarer and Pringle, 1987]. Plasmid YEp24 was described previously [Botstein et al., 1979; YEp24(CDC11)S] is a CDC11-containing derivative [Lillie et al., submitted].

The S. cerevisiae strains used are listed in Table 1. Except as noted, these strains were grown with rotary shaking in the rich, glucose-containing medium YM-P [Lillie and Pringle, 1980] at ~23°C. Strain TD1 was propagated in the appropriate selective media [Sherman et al., 1986] either without plasmid or after transformation with YEp24 or YEp24(CDC11)S. Temperature-sensitive cell-division-cycle mutant strains were grown to ~10^7 cells/ml at ~23°C, then shifted to 36°C by dilution into fresh, pre-warmed medium.

**DNA Manipulations**

Standard procedures were used for recombinant DNA manipulations and E. coli transformations [Maniatis et al., 1982], yeast transformations [Hinnen et al., 1978], and the isolation of plasmid DNAs from E. coli [Birnboim and Doly, 1979; Holmes and Quigley, 1981].

**Isolation of Proteins, Gel Electrophoresis, and Protein Blotting**

Total E. coli proteins were isolated after growth under the appropriate inducing conditions as described previously [Haarer and Pringle, 1987]. To prepare total yeast proteins, cells were grown to ~10^7 cells/ml in the appropriate medium. Approximately 10^8 cells were then harvested by centrifugation at ~23°C and then

<table>
<thead>
<tr>
<th>Strain</th>
<th>Relevant genotype</th>
<th>Source or reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>C276</td>
<td>MATa/MATa (Ts+, prototrophic diploid)</td>
<td>Wilkinson and Pringle [1974]</td>
</tr>
<tr>
<td>TD1</td>
<td>MATa ura3 his3 trp1 (Ts+)</td>
<td>G. Fink</td>
</tr>
<tr>
<td>CP1AB-1AA</td>
<td>MATa/MATa (Ts+, prototrophic diploid)</td>
<td>Paquin and Adams [1982]</td>
</tr>
<tr>
<td>CP1AB-1BB</td>
<td>MATa/MATa (Ts+, prototrophic diploid)</td>
<td>Paquin and Adams [1982]</td>
</tr>
<tr>
<td>LH104-H01</td>
<td>MATa/MATa cdc3-1/cdc3-1</td>
<td>Adams and Pringle [1984]</td>
</tr>
<tr>
<td>LH17012-H01</td>
<td>MATa/MATa cdc10-1/cdc10-1</td>
<td>Adams and Pringle [1984]</td>
</tr>
<tr>
<td>JPT194-H01</td>
<td>MATa/MATa cdc11-6/cdc11-6</td>
<td>Adams and Pringle [1984]</td>
</tr>
<tr>
<td>JPTA1493-H01</td>
<td>MATa/MATa cdc12-6/cdc12-6</td>
<td>Adams and Pringle [1984]</td>
</tr>
</tbody>
</table>
resuspended and processed further at 0–4°C. After one wash in distilled water, the cells were suspended in 100 μl lysis buffer with protease inhibitors, essentially as described previously [Haarer and Pringle, 1987], and ruptured by vortexing for several short periods with 0.5 mm glass beads. After the beads were removed by brief centrifugation, the lysate was either frozen at −70°C until further use or diluted 1:1 with 2× loading buffer (58 mM Tris-HCl [pH 6.8], 735 mM β-mercaptoethanol, 10% glycerol, 2% sodium dodecyl sulfate [SDS], 0.01% bromophenol blue) and loaded directly onto a polyacrylamide gel. Total protein concentrations were normalized by the method of Bradford [1976].

SDS-polyacrylamide gels (8%, 0.7 mm thick) and the Laemmli [1970] buffer system were used for all protein electrophoresis. When desired, proteins were visualized by staining in 0.5% Coomassie Brilliant Blue R, 45% methanol, 10% acetic acid, and destaining in 20% methanol, 10% acetic acid. Alternatively, proteins were blotted to nitrocellulose [Burnette, 1981; Towbin et al., 1979] using a TE42 electroblotter (Hoefer, San Francisco, CA) with a current of 1 A for 2 h. The blotted proteins were visualized by staining the nitrocellulose for 10 min in 0.2% Ponceau S in 0.3% trichloroacetic acid and destaining in PBS [Pringle et al., 1989]. Blots were then either used for affinity purification (see below) or stained with antibodies as described previously [Pringle et al., 1989].

Preparation of Antigens and Antibodies

Total proteins were isolated from E. coli strain BMH71-18 harboring fusion plasmid pUR288 (CDC11)12 (see Results) and from E. coli strain HB101 harboring fusion plasmid pATH3(CDC11)14 (see Results), and the β-galactosidase-Cdc11p and anthranilate synthase-Cdc11p fusion proteins were isolated by gel electrophoresis. For immunization, gel slices containing 50–100 μg of fusion protein were homogenized, mixed at 2:3 with Freund’s adjuvant (complete adjuvant for the initial injection; incomplete adjuvant for all subsequent injections) and injected subcutaneously into New Zealand White rabbits. Serum samples were prepared [Hurn and Chantler, 1980] from blood collected just after the first injection (preimmune sera) and 2–3 weeks after each booster injection (immune sera). Cdc11p-specific antibodies were affinity purified using nitrocellulose blots of the fusion proteins as described previously [Pringle et al., 1989]. Except as noted, purification was done in two steps. Antibodies raised against the β-galactosidase-Cdc11p fusion were purified first on the anthranilate synthase-Cdc11p fusion and then on the β-galactosidase-Cdc11p; antibodies raised against the anthranilate synthase-Cdc11p fusion were purified first on the β-galactosidase-Cdc11p fusion and then on the anthranilate synthase-Cdc11p fusion.

Morphological Observations

In most cases, cells were fixed by adding formaldehyde directly to the culture medium to a final concentration of 3.7% and incubating for 2–3 h at −23°C [Pringle et al., 1989]. With some antibody preparations, immunofluorescence was more successful when cells were initially fixed by adding glutaraldehyde directly to the culture medium to a final concentration of 0.025% and incubating for 3 min, then washed in PBS, resuspended in 3.7% formaldehyde in PBS, and incubated for an additional 20 min at −23°C [Chen et al., 1985]. Indirect immunofluorescence, staining of actin with rhodamine-phalloidin, and staining of nuclear DNA with DAPI were performed as described previously [Pringle et al., 1989]. Proportions of budded and unbudded cells were determined by phase-contrast microscopy after sonication to disperse clumps [Pringle and Mor, 1975].

Other Methods

To depolymerize microtubules, cells were treated with nocodazole as described previously [Jacobs et al., 1988]. To arrest cell proliferation with α-factor, strain CP1AB-1AA was grown to a density of ~10⁷ cells/ml and diluted into fresh medium to a concentration of 2×10⁶ cells/ml. α-Factor (from a stock solution of 1 mg/ml in water) was then added to a final concentration of 5 μg/ml, and incubation was continued for 160 min at ~23°C. For mating experiments, strains CP1AB-1AA and CP1AB-1BB were grown separately to ~10⁷ cells/ml. Equal numbers of cells of each mating type were then mixed and collected onto 0.45 μm Millipore (Bedford, MA) filters to yield ~2.5×10⁷ cells per 4.7 cm diameter filter. The filters were then placed on YPD plates [Sherman et al., 1986] and incubated for 1.5–2 h at ~23°C, after which the cells were collected by washing the filters with two 5-ml changes of 0.9% NaCl containing 3.7% formaldehyde.

RESULTS

Construction of lacZ:CDC11 and trpE:CDC11 Gene Fusions

Fusions of CDC11 to the E. coli lacZ and trpE genes were constructed as described in Figure 1. Analysis of the CDC11 DNA sequence [Haurer et al., submitted] predicted that these constructions would result in in-frame fusions. As expected, induction of cells containing plasmid pPATH3(CDC11)14 resulted in the synthesis of an ~72 kD fusion protein (Fig. 2A, lanes 1–3), and induction of cells containing plasmid pUR288(CDC11)12 resulted in the synthesis of an ~150 kD fusion protein (Fig. 2A, lanes 4–6).

Production of Antibodies Specific for Cdc11p

The β-galactosidase-Cdc11p and anthranilate synthase-Cdc11p fusion proteins were used separately to elicit antibody production in rabbits (see Materials and
Fig. 1. Construction of lacZ:CDC11 and trpE:CDC11 gene fusions. The 1.165 kb CluI-ScaI fragment from YEp24 (CDC11)S was inserted into fusion vectors pUR288 and pATH3 to produce plasmids pUR288(CDC11)12 and pATH3(CDC11)14, respectively. In each case, the vector was linearized with BamHI, followed by treatment with calf intestine alkaline phosphatase and the Klenow fragment of DNA polymerase to produce blunt ends, and then ligated to the gel-purified CluI-ScaI fragment, which had itself been treated with Klenow fragment to produce two blunt ends. Fusions in the correct orientation were identified by restriction site analysis (not shown). Large solid arrows represent the CDC11 coding region, as inferred from DNA sequence analysis [Haarer et al., submitted]; open boxes represent adjacent yeast DNA; stippled boxes represent the lacZ and trpE coding regions; and thin lines represent either pBR322-derived or E. coli DNA. Small arrows indicate the directions of transcription for the two fusion genes. Restriction sites are indicated: B, BamHI; C, CluI; S, SalI; Sa, Sau3A; Sc, ScaI.

Methods). Immunoblotting showed that each of the resulting crude antisera was able to recognize both fusion proteins in crude extracts of E. coli strains harboring the appropriate fusion plasmids (Fig. 2B and data not shown). Therefore, the sera appeared to contain antibodies specific for Cdc11p determinants, which are common to both fusion proteins.

Affinity-purified antibodies (see Materials and Methods) recognized an ~55 kD protein in blots of total proteins from CDC11 (wild-type) cells containing no plasmid (Fig. 2C, lane 1) or plasmid YEp24 (Fig. 2C, lane 3). A stronger reaction at the same position was observed in extracts of the same strain harboring a high-copy-number plasmid containing the entire CDC11 coding region (Fig. 2C, lane 2), indicating that the ~55 kD protein is the authentic CDC11 gene product. The estimated molecular weight of ~55 kD is somewhat greater than the 47.7 kD predicted from DNA sequence analysis [Haarer et al., submitted]; the reason for this discrepancy is not yet understood. In blots of the overproducing strain, two additional polypeptides of ~30 and ~40 kD were detectable (Fig. 2C, lane 2). As these polypeptides were not visible in extracts of control strains (Fig. 2C, lanes 1,3), they probably represent breakdown products of Cdc11p.

When the affinity-purified antibodies were used at high concentrations on blots of total proteins from wild-type cells, they reacted weakly with four other proteins in addition to Cdc11p (Fig. 2D, lanes 1–4). Three of these proteins (those of ~66 kD, ~43 kD, and ~37 kD) comigrated approximately with Cdc3p, Cdc12p, and Cdc10p, respectively [Haarer and Pringle, 1987; data not shown]; such possible cross-reactivity would not be surprising given the sequence similarities between these proteins and Cdc11p [Haarer et al., submitted].

Immunofluorescence Localization of Cdc11p in Wild-type and Mutant Cells

Staining of wild-type cells with the affinity-purified antibodies revealed a localization for Cdc11p (Fig. 3A,G) similar to that observed previously for Cdc3p, Cdc10p, and Cdc12p [Haarer and Pringle, 1987; Kim et al., 1991; Kim et al., manuscript in preparation]. In cells with buds of various sizes, the staining revealed a double-band structure surrounding the mother-bud neck (Fig. 3A, cells 1–4). This staining pattern is consistent with the hypothesis that Cdc11p is a constituent of the ring of 10 nm filaments that lies directly subjacent to the plasma membrane in the neck region [Byers and Goetsch, 1976a; Byers, 1981; Haarer and Pringle, 1987; see also below]. Evidence that the stain-
Fig. 2. A: Identification of anthranilate synthase-Cdc11p and β-galactosidase-Cdc11p fusion proteins by SDS-polyacrylamide gel electrophoresis. Lanes 1–3: Total proteins prepared from E. coli strain HB101 containing (lane 1) no plasmid; (lane 2) plasmid pATH3; or (lane 3) plasmid pATH3(CDC11)14. Lanes 4–6: Total proteins prepared from E. coli strain BMH71-18 containing (lane 4) no plasmid; (lane 5) plasmid pUR288; or (lane 6) plasmid pUR288(CDC11)12. In all cases, strains were propagated under inducing conditions [Haarer and Pringle, 1987]. The approximate sizes of the truncated anthranilate synthase and P-galactosidase proteins encoded by the vectors and of the fusion proteins are given in kilodaltons. B: Recognition of p-galactosidase-Cdc11p and anthranilate synthase-Cdc11p fusion proteins on blots by antisera raised against the fusion proteins. Total proteins prepared from (lane 1) E. coli strain BMH71-18 containing plasmid pUR288(CDC11)12 or (lane 2) E. coli strain HB101 containing plasmid pATH3(CDC11)14 were electrophoresed, blotted to nitrocellulose, and reacted with antibodies. The primary antibodies used were 1:200 dilutions of crude sera obtained from rabbits immunized with the (lane 1) anthranilate synthase-Cdc11p or (lane 2) P-galactosidase-Cdc11p fusion proteins. The secondary antibody used was a 1:250 dilution of HRP-conjugated goat anti-rabbit-IgG. The approximate sizes of the fusion proteins are given in kilodaltons. C: Identification of Cdc11p using affinity-purified antibodies. Total cellular proteins prepared from strain TD1 containing (lane 1) no plasmid, (lane 2) plasmid YEp24(CDC11)S, or (lane 3) plasmid YEp24 were electrophoresed, blotted to nitrocellulose, and reacted with a 1:200 dilution of affinity-purified antibodies raised against the anthranilate synthase-Cdc11p fusion protein. (The antibodies used were those obtained after the first boost of rabbit 4, Table 2. For this experiment, the affinity purification used only the first step of the two-step procedure described in Materials and Methods.) The secondary antibody used was a 1:250 dilution of HRP-conjugated goat anti-rabbit-IgG. The position of the putative wild-type CDC11 gene product at ~55 kD is indicated. The lower two arrowheads indicate the positions of a pair of additional bands visible only in lane 2 (see text). D: Cross-reactivity of the affinity-purified Cdc11p-specific antibodies with other yeast proteins. Total cellular proteins isolated from strain C276 were electrophoresed, blotted to nitrocellulose, and reacted with (lane 1) tenfold, (lane 2) 25-fold, (lane 3) 50-fold, (lane 4) 100-fold, (lane 5) 500-fold, and (lane 6) 2,500-fold serial dilutions of affinity-purified antibodies raised against the β-galactosidase-Cdc11p fusion protein. (The antibodies used were those obtained after the fifth boost of rabbit 1, Table 2.) The secondary antibody used was a 1:250 dilution of HRP-conjugated goat anti-rabbit-IgG. The approximate sizes of Cdc11p and of the weakly cross-reacting proteins are given in kilodaltons.

The staining pattern observed reflects the localization of Cdc11p, and not that of one of the cross-reacting species (Fig. 2D), was obtained by repeating the staining using the primary antibodies at various dilutions. Staining of the neck region was weakly visible even when the antibodies were used at a 1:250 dilution (data not shown); when the same antibody preparation was used at this concentration to stain Cdc11p on blots, staining was still strong, whereas no staining of cross-reacting species was detectable (Fig. 2D). In dividing cells, the bands of fluorescence appeared as separate structures of enlarged diameter and diminished staining intensity (Fig. 3A, cell 5).

Surprisingly, most preparations of affinity-purified Cdc11p-specific antibodies also appeared to stain both the nuclear and cytoplasmic microtubules. With three of the four rabbits immunized, the putative microtubule staining was undetectable with the preimmune sera but was strong with the antibodies obtained after one boost with fusion protein (Fig. 3B,C; Table 2, rabbits 1, 2, and 4). With the fourth rabbit, the putative microtubule staining was weakly detectable with the
Fig. 3. Immunofluorescence localization of Cdc11p in wild-type (strain C276) and mutant cells. A: Wild-type cells stained with a 1:5 dilution of antibodies affinity-purified from serum obtained after a fifth boost with β-galactosidase-Cdc11p fusion protein (rabbit 1 of Table 2); the secondary antibody was rhodamine-conjugated goat anti-rabbit-IgG used at a 1:400 dilution. Individual cells are labeled for reference in the text. B–G: Wild-type cells stained with preimmune sera (B,E) or with immune sera obtained after the first (C,F) or fifth (D,G) boost with the β-galactosidase-Cdc11p (B–D; rabbit 1 of Table 2) or anthranilate synthase-Cdc11p (E–G; rabbit 3 of Table 2) fusion protein. Preimmune sera were prepared for immunofluorescence using a procedure parallel to that used for affinity purification of Cdc11p-specific antibodies from immune sera and were then used without dilution; affinity-purified immune sera were used at a 1:1 dilution. The secondary antibody was rhodamine-conjugated goat anti-rabbit-IgG used at a 1:400 dilution. The arrowheads in panel E indicate the stained microtubules. H–K: Wild-type cells double-stained with antibodies raised against the β-galactosidase-Cdc11p fusion protein (H,I) and antitubulin antibodies (J,K) either prior to nocodazole treatment (H,J) or after treatment with nocodazole for 1 h (H,K). The Cdc11p-specific antibodies were affinity purified from serum obtained after the first boost of rabbit 1 (Table 2) and used at a 1:1 dilution. The rat monoclonal antitubulin antibody was used at a 1:100 dilution. The secondary antibodies were FITC-conjugated goat anti-rabbit-IgG used at 1:100 dilution and rhodamine-conjugated goat anti-rat-IgG used at 1:200 dilution. L–O: Mutant cells stained with the same primary and secondary antibody preparations and concentrations as used in panel A. L,N,O: JPT194-HO1 (cdc11) cells grown at ~23°C (L) or at 36°C for 0.5 h (N) or 2.5 h (O). M: LH17012-HO1 (cdc10) cells grown at 36°C for 0.5 h. The scale for all panels is shown by the bar in panel J, representing 5 μm.
preimmune serum and was stronger after one boost with fusion protein (Fig. 3E, F; Table 2, rabbit 3). With at least some of the sera obtained after one boost, the staining of microtubules was particularly strong (relative to that of the neck regions) when the standard formaldehyde fixation was used (see Materials and Methods). Preimmune sera were prepared using a parallel procedure (mock affinity purification). Preparations of immune and preimmune sera were then used after 1:1 dilution and without dilution, respectively.

Rabbits 1 and 2 were immunized with the β-galactosidase-Cdc11p fusion protein; rabbits 3 and 4 were immunized with the anthranilate synthase-Cdc11p fusion protein.

**TABLE 2. Intensity of Staining of Microtubules and Neck Regions Using Preimmune Sera and Affinity-purified Immune Sera**

<table>
<thead>
<tr>
<th>Source of serumb</th>
<th>Rabbit 1</th>
<th>Rabbit 2</th>
<th>Rabbit 3</th>
<th>Rabbit 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preimmune</td>
<td>-/+ -/+</td>
<td>-/+ -/+</td>
<td>-/+ -/+</td>
<td>-/+ -/+</td>
</tr>
<tr>
<td>Immune (after first boost&lt;sup&gt;c&lt;/sup&gt;)</td>
<td>++/+ +/ +/ +</td>
<td>++/ +/+</td>
<td>++/ +/+</td>
<td>++/ +/+</td>
</tr>
<tr>
<td>Immune (after fifth boost&lt;sup&gt;d&lt;/sup&gt;)</td>
<td>++/+ +/+</td>
<td>++/ +/+</td>
<td>++/ +/+</td>
<td>++/ +/+</td>
</tr>
</tbody>
</table>

<sup>a</sup>Intensities of staining were scored subjectively on a scale from undetectable (−) to very intense (;++++.). Each entry shows the intensity of staining of microtubules (left of slash) and of neck regions (right of slash).

<sup>b</sup>Cdc11p-specific antibodies were purified from the immune sera as described in Materials and Methods.

<sup>c</sup>Preimmune sera were prepared using a parallel procedure (mock affinity purification).

<sup>d</sup>Preimmune sera were prepared using a parallel procedure (mock affinity purification).

<sup>e</sup>That is, after the initial immunizing injection plus one booster injection.

<sup>f</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>g</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>h</sup>That is, after the initial immunizing injection plus one booster injection.

<sup>i</sup>That is, after the initial immunizing injection plus one booster injection.

<sup>j</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>k</sup>That is, after the initial immunizing injection plus one booster injection.

<sup>l</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>m</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>n</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>o</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>p</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>q</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>r</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>s</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>t</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>u</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>v</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>w</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>x</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>y</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>z</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>aa</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>ab</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>ac</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>ad</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>ae</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>af</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>ag</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>ah</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>ai</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>aj</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>ak</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>al</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>am</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>an</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>ao</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>ap</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>aq</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>ar</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>as</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>at</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>au</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>av</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>aw</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>ax</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>ay</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>az</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>ba</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>bb</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>bc</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>bd</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>be</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>bf</sup>That is, after the initial immunizing injection plus five booster injections.

<sup/bg</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>bg</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>bh</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>bi</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>bj</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>bk</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>bl</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>bm</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>bn</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>bo</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>bp</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>bq</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>br</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>bs</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>bt</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>bu</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>bv</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>bw</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>bx</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>by</sup>That is, after the initial immunizing injection plus five booster injections.

<sup>bz</sup>That is, after the initial immunizing injection plus five booster injections.
Fig. 4. Localization of Cdc11p and of actin in unbudded wild-type cells and localization of Cdc11p in shmoos and zygotes. A: Unbudded wild-type cells (strain C276) stained with the same primary and secondary antibody preparations and concentrations as used in Figure 3A. Individual cells are labeled for reference in the text. B,C: Unbudded strain C276 cells double-stained with Cdc11p-specific antibodies (B) and rhodamine-phalloidin (C). The primary antibody used was a 1:4 dilution of a separate affinity-purified preparation from the same serum as that used in Figure 3A; the secondary antibody was FITC-conjugated goat anti-rabbit-IgG used at a 1:100 dilution. Rhodamine-phalloidin was used at a 1:10 dilution of the stock solution supplied by the manufacturer (see Materials and Methods). Individual cells are labeled for reference in the text. Small arrowheads indicate “new” Cdc11p rings; large arrowheads indicate “old” Cdc11p rings. D: Shmoo (strain CP1AB-1AA) observed after treatment with a-factor for 160 min and staining with a 1:5 dilution of the same primary antibody preparation as used in panel B; the secondary antibody was as used in Figure 3A. The arrowhead indicates the localization of staining in the shmoo tip. E: Zygotes formed by mating strains CP1AB-1AA and CP1AB-1BB and stained either as in panel D (zygote 1) or as in panel A (zygotes 2 and 3). Individual zygotes are labeled for reference in the text. The arrowheads indicate localized staining in the conjugation bridge. The scale for all panels is shown by the bar in panel D, representing 5 μm.

Remarkably, nearly all such cells displayed rings of Cdc11p. These rings were of two types: brightly stained rings of smaller diameter (Fig. 4A, cells 3–5) and less brightly stained rings of larger diameter (Fig. 4A, cells 1, 2, and 5). In a sample of 657 unbudded cells, 6.5% had one small ring only, 58% had one large ring only, 35% had one ring of each type (typically at opposite

Timing of Events at the Budding Site

Electron microscopy has suggested that the ring of 10 nm filaments appears approximately coincident with bud emergence and disappears just prior to cytokinesis [Byers and Goetsch, 1976a; Byers, 1981]. We asked if the localization of Cdc11p to the budding site corresponded to this apparent timing of filament assembly and disassembly by examining the immunofluorescence patterns of the unbudded cells from an exponentially growing population of wild-type cells. Remarkably, nearly all such cells displayed rings of Cdc11p. These rings were of two types: brightly stained rings of smaller diameter (Fig. 4A, cells 3–5) and less brightly stained rings of larger diameter (Fig. 4A, cells 1, 2, and 5). In a sample of 657 unbudded cells, 6.5% had one small ring only, 58% had one large ring only, 35% had one ring of each type (typically at opposite
poles; see Fig. 4A, cell 5), and just 0.2% had no visible ring. The similarities of the small rings to those found on cells with small buds (cf. Fig. 3A, cell 1) and of the large rings to those found on dividing mother and daughter cells (cf. Fig. 3A, cell 5) suggest that the small rings are formed in anticipation of subsequent bud emergence and that the large rings are those remaining from the previous cell cycles. This interpretation is supported by the presence of both types of rings on some cells, by the coincidence of both small and large rings with concentrations of actin (see below), and by related observations (including studies of synchronized cultures) made using Cdc3p-specific and Cdc10p-specific antibodies [Kim et al., 1991; Kim et al., manuscript in preparation]. In addition, when cdc3 and cdc11 mutants were shifted to restrictive temperature for 0.5 h and then stained with affinity-purified antibodies, no localization of Cdc11p was detected in unbudded cells, consistent with the inability of these mutants to form new rings of 10 nm filaments at restrictive temperature [Byers and Goetsch, 1976; Adams, 1984] (cf. also Fig. 3N and associated text).

If our interpretation of the two types of rings is correct, we can calculate the approximate timing of appearance and disappearance of a detectable ring of Cdc11p. For the exponentially growing population sampled, the generation time was 119 min, and 29% of the cells were unbudded (as determined by phase-contrast microscopy); thus, the mean unbudded period would be ~ 27 min [Hartwell and Unger, 1977]. By similar calculation, the ring of Cdc11p would appear ~ 13 min before bud emergence and linger ~ 24 min after cell division, on average. In some cells, the “old” ring of Cdc11p persisted throughout the entire unbudded phase and was still evident early in the next budding cycle (data not shown).

As actin also becomes concentrated at the budding site and appears to play a critical role in bud emergence and bud growth (see Introduction), it was of interest to determine the relative timing of the arrival of actin and of Cdc11p at presumptive budding sites. To do this, exponentially growing wild-type cells were double-stained with Cdc11p-specific antibodies and with rhodamine-phalloidin. In a sample of 394 unbudded cells, 175 of 175 “new” Cdc11p rings observed had associated clusters of actin (Fig. 4B,C, cells 1–3, small arrowheads), as did 346 of 362 “old” Cdc11p rings (Fig. 4B,C, cells 2–5, large arrowheads). In addition, one cell with a “new” Cdc11p ring and associated actin cluster at one pole displayed a second actin cluster without an associated ring of Cdc11p at the opposite pole, whereas 18 cells with an “old” Cdc11p ring and associated actin cluster at one pole displayed a second actin cluster without an associated ring of Cdc11p at the opposite pole (Fig. 4B,C, cell 1). Only one cell in this sample failed to show any ring of Cdc11p; it possessed an actin cluster at one pole. From these results, we infer that the actin concentration at a previous budding site usually (but not always) becomes undetectable a short time before the ring of Cdc11p becomes undetectable, whereas the actin cluster at a future budding site normally forms coincident with or shortly before the appearance of a detectable ring of Cdc11p at that site.

Localization of Cdc11p in Shmoos and Zygotes

Cells engaged in mating or responding to mating pheromone undergo localized changes in cell-wall organization (including chitin deposition) that appear related to those occurring in budding cells. Thus, it was of interest to ask if Cdc11p also localized to the sites of cell-wall reorganization in shmoos and zygotes. Immunofluorescence staining of shmoos typically revealed a faint, but distinct, band of staining around the growing tip (Fig. 4D), corresponding approximately to the region of chitin deposition in such cells (unpublished observations). In zygotes observed soon after fusion, Cdc11p could occasionally be detected faintly in the conjugation bridge (Fig. 4E, zygote 1). The staining pattern was variable, sometimes appearing as two weakly staining bands on either side of the point of contact, again corresponding approximately to the regions of chitin deposition (unpublished observations). Zygotes that had initiated budding possessed the typical pattern of staining seen in budding cells (Fig. 4E, zygotes 2 and 3); staining of the conjugation bridge was rarely, if ever, observed in zygotes at this stage.

DISCUSSION

The S. cerevisiae CDC3, CDC10, CDC11, and CDC12 genes and their products are involved in the morphogenetic events of the cell cycle: mutation of any of these genes produces pleiotropic morphogenetic abnormalities including a failure to form the ring of 10 nm filaments that normally lies immediately subjacent to the plasma membrane in the mother-bud neck (see Introduction). These observations suggested that the CDC3, CDC10, CDC11, and CDC12 products might be constituents of the ring of 10 nm filaments and, thus, that the other morphological abnormalities observed in the mutants might be consequences of the failure to form these filaments. Evidence supporting this hypothesis has been obtained previously using antibodies specific for Cdc3p, Cdc10p, and Cdc12p in immunofluorescence experiments on wild-type and mutant cells, all three proteins localize as expected for constituents of the 10 nm filaments [Haarer and Pringle, 1987; Kim et al., 1991; Kim et al., manuscript in preparation]. Given the similar phenotypes of the cdc3, cdc10, cdc11, and cdc12 mutants, the extensive homologies in amino acid sequence among the predicted CDC3, CDC10, CDC11, and CDC12 products [Haarer et al., submitted], and the extensive genetic evidence for interactions among these genes and/or their products [Pringle et al., 1986; Lillie et al., submitted], we anticipated that Cdc11p would display a similar localization.
To investigate this issue, we used β-galactosidase-Cdc1lp and anthranilate synthase-Cdc1lp fusion proteins to elicit and affinity purify antibodies that could recognize Cdc1lp in blots of yeast proteins. These antibodies appeared to be highly but not completely specific for Cdc1lp: when the highest-titer antibodies (those obtained after five boosts with fusion protein) were used at high concentrations to stain blots of yeast proteins, four faint bands were observed in addition to the very strong band of Cdc1lp. Three of these bands had mobilities corresponding to those of Cdc3p, Cdc10p, and Cdc12p and might in fact be those proteins; such cross reaction would not be surprising given the extensive sequence similarities among these proteins [Haarer et al., submitted]. As the reaction with Cdc1lp appears to be ≥ 1,000-fold stronger than the reaction with any of the other species, it seems likely that the immunofluorescence patterns observed reflect the true localization of Cdc1lp, and not that of any of the cross-reacting species. However, we cannot exclude the possibility that a protein recognized weakly (or not at all) on blots is recognized more strongly when presented in fixed cells, and thus contributes significantly to the immunofluorescence patterns observed.

That such concerns may not be trivial is suggested by the perplexing observation that most of our preparations of ostensibly Cdc1lp-specific antibodies stained not only the region of the 10 nm filaments but also both the cytoplasmic and nuclear microtubules. This staining was particularly prominent with the sera obtained after one boost with the fusion proteins, where the microtubule staining was in some cases brighter than the staining of the 10 nm filaments, particularly when the standard formaldehyde fixation protocol was used (see Materials and Methods). There appear to be three possible explanations for these observations: 1) production of antibodies specific for tubulin or some other microtubule-associated protein might have been nonspecifically stimulated by the immunization regimen; 2) tubulin or some other microtubule-associated protein might share one or more epitopes with Cdc1lp; and 3) a fraction of the Cdc1lp might actually be associated with the microtubules. Possibility 1 is supported by the observations that microtubule-recognizing antibodies were present in the preimmune serum from at least one rabbit, that microtubule-recognizing antibodies have been observed also after immunizing with the totally unrelated protein Dedlp/Spp81p [B. Rahe and J. Pringle, unpublished observations; see also Jamieson et al., 1991], and that immunization with Cdc12p fusion proteins also resulted in an apparently gratuitous induction of unrelated antibodies (recognizing in this case some component of the cell wall) [Haarer and Pringle, 1987]. However, possibility 1 appears difficult to reconcile with the observations that microtubule staining was visible even after two-step affinity purification and that the titer of microtubule-recognizing antibodies was boosted dramatically in all four rabbits during the early stages of immunization. These latter observations appear most consistent with possibility 2 or 3. However, possibility 3 appears difficult to reconcile with the observations that temperature shift of a cdc11 mutant could eliminate staining of the neck filaments without obviously affecting the staining of the microtubules and that the apparent titer of microtubule-recognizing antibodies declined precipitously (to undetectable levels with two rabbits) upon repeated booster injections with the Cdc1lp fusion proteins. Thus, the balance of the evidence appears to favor possibility 2. However, it must be noted that this hypothesis itself is somewhat difficult to reconcile with the failure to observe more prominent bands of cross-reacting proteins on blots (Fig. 2C,D; results similar to those of Fig. 2C were also obtained with the first-boost serum from rabbit 1, with which the microtubule staining was even stronger (Table 2)). Thus, we cannot exclude the interesting possibility that a fraction of the Cdc1lp is associated with the microtubules.

With these caveats only noted, the intracellular localization of Cdc1lp in both wild-type and mutant cells appears to be essentially the same as that of Cdc3p, Cdc10p, and Cdc12p. Moreover, this localization is consistent with that expected for a constituent of the 10 nm filaments in the mother-bud neck, except for one apparent discrepancy. Electron microscopy has suggested that the ring of 10 nm filaments assembles coincident with bud emergence and disassembles just prior to cytokinesis [Byers and Goetsch, 1976a; Byers, 1981]. In contrast, the immunofluorescence observations indicate that Cdc1lp forms a well organized ring at the presumptive budding site well before bud emergence and lingers at that site well after cytokinesis (indeed, often throughout the entire subsequent unbudded phase). Similar observations have been made for Cdc3p and Cdc10p [Kim et al., 1991; Kim et al., manuscript in preparation]. The apparent discrepancy may well have a trivial explanation in the undoubted difficulty of visualizing the 10 nm filaments by electron microscopy; this problem would be especially severe in examining unbudded cells [B. Byers, personal communication]. However, the interesting possibility remains that the filament-associated proteins can assemble at the budding site, and perhaps function, without assembling into the higher-order structure visualized in the electron microscope as 10 nm filaments.

The question of the relationship between the formation of filaments and the function of these proteins is also raised by the observations on shmoos and zygotes. The diffuse and rather faint immunofluorescence staining observed with these cells using Cdc1lp-specific (this study) or Cdc3p-, Cdc10p-, or Cdc12p-specific [Kim et al., 1991; Kim et al., manuscript in preparation] antibodies is not suggestive of a ring of filaments such as that found in budding cells. Moreover, to our knowledge, 10 nm filaments have not been observed in shmoos or zygotes by electron microscopy. However, it
must be noted that there is also no good evidence that the proteins actually function in such cells. Although the localization of the proteins to regions of active cell-wall reorganization is suggestive, the staining of zygotes was not consistent, and shifts of cdc3, cdc10, and cdc12 mutants to restrictive temperature produced no immediate loss of mating ability [Reid and Hartwell, 1977].

In any case, it should be stressed that the most economical interpretation of the available data is that Cdc3p, Cdc10p, Cdc11p, and Cdc12p are the primary constituents of the 10 nm filaments. If so, then the novelty of these proteins' sequences [Haarer et al., 1987] suggests that these filaments may represent a novel type of eukaryotic cytoskeletal element. We are presently investigating whether similar proteins and filaments exist in other kinds of cells. To date, we have identified several members of this protein family in the evolutionarily distant yeast Saccharomyces pombe [T. Pugh, H.B. Kim, A. Healy, P. Fantes, and J.R. Pringle, manuscript in preparation]; it is not yet clear whether these proteins assemble into filaments like those seen in S. cerevisiae. Preliminary evidence suggests that similar proteins may exist in Drosophila as well (J. Fares and J.R. Pringle, unpublished results).

Meanwhile, there remain many questions about the function of these proteins and filaments in S. cerevisiae. One puzzle is why the assembly and function of the filaments require all four of the known filament-associated proteins. We had hoped that comparing the localizations of Cdc3p, Cdc10p, Cdc11p, and Cdc12p in the various mutants at various times after shift to restrictive temperature would reveal differences that might provide clues to the structural arrangements or order of assembly of the proteins. To date, however, no convincing differences have been observed.

Another set of puzzles concerns the mechanisms by which the organization of the filament-associated proteins at presumptive budding sites is triggered at the appropriate time and at a single, nonrandom [Chant et al., submitted] location. This organization appears to be essentially coincident with that of the actin cytoskeleton at the same sites. As actin localization to these sites may occur slightly earlier than that of the filament-associated proteins (see Results), it is conceivable that the actin cytoskeleton helps direct the filament-associated proteins to the proper site. However, it seems more likely that these are independent events that are both dependent on some common upstream signal(s). It is interesting that the organization of these proteins at presumptive budding sites seems to precede the duplication of the spindle-pole body, as Byers and Goetsch [1975] observed no unbudded cells with duplicated spindle-pole bodies by electron microscopy. Thus, the cytoskeletal organization at the presumptive budding site must be among the earliest events occurring after Cdc28p protein kinase activity is triggered during the cell-cycle-controlling Start event [Pringle and Hartwell, 1981; Wittenberg et al., 1990].

ACKNOWLEDGMENTS

We thank Breck Byers, Hyong Kim, Brian Haarer, Charlie Jacobs, and Sue Lillie for helpful discussions and Sue Lillie for providing plasmid YEp24(CDC11). This work was supported by NIH grant GM31006.

REFERENCES


REFERENCES
Lillie SH, Haarer BK, Bloom L, Coleman KG, Pringle JR (submitted): Isolation and characterization of CDC3, CDC11, and CDC12, three genes controlling morphogenesis in the Saccharomyces cerevisiae cell cycle.